Galectin-3 is a blood marker linked to inflammation, tissue repair, scarring, and heart remodeling. In heart failure, it is used most often as a risk marker rather than as a stand-alone diagnostic test. A high galectin-3 result can suggest a higher chance of future heart failure hospitalization, worsening symptoms, or death, especially when it stays elevated over time. It can also rise with kidney disease, older age, chronic inflammation, and fibrotic conditions outside the heart.
The test is most useful when interpreted with symptoms, exam findings, echocardiogram results, kidney function, and heart failure markers such as BNP or NT-proBNP. A single galectin-3 number does not prove heart failure, identify a heart attack, or show exactly where fibrosis is occurring. It adds a different layer of information: whether the body may be showing more active fibrotic and inflammatory signaling.
- Galectin-3 measures a protein involved in inflammation, fibrosis, and tissue remodeling.
- A commonly used high-risk cutoff is above about 17.8 ng/mL, but lab ranges and assays can differ.
- High galectin-3 is linked with worse heart failure outcomes, not a definite diagnosis by itself.
- Kidney disease can raise galectin-3 and must be considered before interpreting the result.
- No fasting is usually needed for the blood draw unless other tests are ordered at the same time.
- Chest pain, severe shortness of breath, fainting, or sudden swelling needs urgent care, regardless of galectin-3.
Table of Contents
- What the Galectin-3 Blood Test Measures
- Why the Test Is Ordered
- Normal Range, High Galectin-3, and Result Meaning
- Galectin-3, Heart Failure Risk, and Fibrosis
- Common Causes of High Galectin-3
- How Doctors Interpret Galectin-3 With Other Tests
- Preparation, Timing, and Test Limitations
- What to Do After a Galectin-3 Result
What the Galectin-3 Blood Test Measures
The galectin-3 blood test measures the amount of galectin-3 in the bloodstream, usually reported in nanograms per milliliter (ng/mL). Galectin-3 is a carbohydrate-binding protein made by several cell types, including immune cells called macrophages. It plays a role in inflammation, wound repair, cell signaling, and fibrosis.
Fibrosis means excess scar-like tissue forms in an organ. This can happen after long-term injury, pressure, inflammation, or metabolic stress. In the heart, fibrosis can make the heart muscle stiffer, less efficient, and more likely to remodel over time. “Remodeling” means the heart changes in size, shape, thickness, or function after stress or injury.
Galectin-3 is not a “heart-only” protein. It can be involved in the heart, kidneys, liver, lungs, blood vessels, and immune system. This is why the result needs context. A high value may fit with heart failure risk in one person, chronic kidney disease in another, and a broader inflammatory or fibrotic pattern in someone else.
In cardiovascular care, galectin-3 is mainly used as a prognostic biomarker. A prognostic test estimates future risk. It does not work like a rapid heart attack marker, and it does not replace imaging. It gives a signal about biological processes that may make heart failure harder to control.
A useful way to think about it is this: BNP and NT-proBNP reflect heart wall stretch and fluid-pressure stress, troponin reflects heart muscle injury, and galectin-3 reflects more of the inflammation-and-fibrosis side of heart disease. These markers can overlap, but they do not answer the same question.
Why the Test Is Ordered
Galectin-3 is usually ordered when a clinician wants more information about long-term risk in someone with known or suspected heart failure. It may also be included in an advanced cardiac biomarker panel, especially when symptoms, imaging, and standard blood tests do not tell the full story.
The test may be considered in people who have:
- Known chronic heart failure and a need for better risk stratification
- Repeated heart failure flare-ups or hospitalizations
- Shortness of breath where the cause is not clear
- Heart failure with preserved ejection fraction, often called HFpEF
- High blood pressure, diabetes, kidney disease, or obesity with possible cardiac remodeling
- Echocardiogram findings that suggest thickened, stiff, or enlarged heart chambers
- A need to compare several biomarkers over time
Galectin-3 is not typically ordered as the first test for chest pain, a suspected heart attack, or sudden severe shortness of breath. In urgent settings, doctors usually rely on symptoms, exam findings, electrocardiogram results, oxygen level, chest imaging, and faster-acting markers such as troponin and BNP/NT-proBNP.
For heart failure evaluation, galectin-3 is most helpful when used beside BNP and NT-proBNP results. Natriuretic peptides rise when the heart is stretched by pressure or fluid overload. Galectin-3 adds a different signal related to inflammation and fibrotic remodeling.
A clinician may also order galectin-3 when a patient’s symptoms seem out of proportion to standard test results. For example, a person may have mild BNP elevation but significant exercise intolerance and an echocardiogram showing diastolic dysfunction. Galectin-3 may help frame whether a fibrotic process could be contributing to risk, although it cannot prove the mechanism by itself.
Normal Range, High Galectin-3, and Result Meaning
Galectin-3 does not have one universal “normal range” that applies perfectly to every person and every laboratory. Different assays, patient populations, and reporting systems can produce different reference intervals. Many heart failure studies and some clinical reports use about 17.8 ng/mL as a commonly cited cutoff for higher risk.
A result should always be compared with the reference interval printed on the lab report. The same number may be interpreted differently depending on the assay, kidney function, age, and reason the test was ordered.
| Galectin-3 pattern | Possible meaning | Common follow-up |
|---|---|---|
| Lower or within the lab range | Lower fibrotic/inflammatory signal from this marker; does not rule out heart disease | Review symptoms, BNP or NT-proBNP, echocardiogram, kidney tests, and overall risk |
| Near the upper limit | May be borderline or mildly increased depending on the lab and clinical setting | Repeat testing may be considered if the result will change management |
| Above about 17.8 ng/mL | Often treated as a higher-risk range in heart failure research and some clinical use | Look for heart failure severity, kidney disease, inflammation, and fibrosis-related causes |
| Persistently high or rising | May suggest ongoing risk, especially in chronic heart failure | Compare with symptoms, weight changes, fluid status, eGFR, BNP/NT-proBNP, and imaging |
A high galectin-3 result does not tell you that you are having a heart attack. Heart attacks are evaluated with symptoms, ECG changes, and troponin testing. When heart muscle injury is the concern, troponin I and troponin T are far more direct markers.
A low galectin-3 result is usually not considered a problem. Unlike some nutrients, hormones, or blood counts, there is usually no disease state diagnosed by “too little” galectin-3 in routine clinical care. The value is mainly used to identify higher-risk patterns rather than deficiency.
A single elevated result should not cause panic. It is a signal to interpret, not a verdict. The same result can carry different meaning in a 35-year-old with normal kidney function and no symptoms compared with an 82-year-old with chronic kidney disease, atrial fibrillation, and established heart failure.
Galectin-3, Heart Failure Risk, and Fibrosis
Galectin-3 became important in heart failure research because it sits close to two processes that drive disease progression: inflammation and fibrosis. When the heart faces long-term stress, immune cells and fibroblasts can become more active. Fibroblasts are cells that produce collagen and other structural proteins. Too much collagen can make the heart muscle stiffer.
A stiff heart may not relax well between beats. This can raise filling pressures and contribute to shortness of breath, exercise intolerance, swelling, and fatigue. This pattern is especially relevant in heart failure with preserved ejection fraction, where the pumping percentage may look normal but filling and relaxation are impaired.
In heart failure with reduced ejection fraction, galectin-3 may also reflect remodeling and worse prognosis. The marker is not limited to one heart failure subtype. It has been studied in chronic heart failure, acute decompensated heart failure, HFpEF, and broader cardiovascular risk populations.
Galectin-3 may be useful because fibrosis is not always easy to measure with routine blood tests. Echocardiography can show chamber size, wall thickness, valve disease, ejection fraction, and diastolic patterns. Cardiac MRI can sometimes identify scar or tissue changes more directly. Galectin-3 adds a blood-based clue, but it cannot show where fibrosis is located or how much tissue is scarred.
The marker is best viewed as part of a risk picture. A person with elevated galectin-3, high NT-proBNP, reduced exercise capacity, worsening kidney function, and abnormal echocardiogram findings is different from a person with isolated mild galectin-3 elevation and otherwise reassuring results.
Galectin-3 may also overlap with soluble ST2, another heart failure risk marker related to cardiac stress, inflammation, and remodeling. Clinicians sometimes compare these markers when standard results leave uncertainty. For a related marker, see soluble ST2 testing.
Common Causes of High Galectin-3
High galectin-3 can happen for several reasons. Heart failure is one important cause, but it is not the only one. The most common interpretation mistake is assuming that an elevated value always comes from the heart.
Possible causes and contributors include:
- Chronic heart failure
- Acute worsening of heart failure
- Heart failure with preserved ejection fraction
- Left ventricular hypertrophy from long-term high blood pressure
- Atrial fibrillation and other chronic cardiac stress states
- Chronic kidney disease or reduced eGFR
- Older age
- Diabetes and insulin resistance
- Obesity and metabolic inflammation
- Liver fibrosis or chronic liver disease
- Lung fibrosis or chronic inflammatory lung disease
- Autoimmune or inflammatory conditions
- Recent infection or systemic inflammation
- Certain cancers and fibrotic tissue processes
Kidney function deserves special attention. Galectin-3 levels often rise when kidney function is reduced. If creatinine is high or eGFR is low, the result may reflect both cardiovascular and kidney-related risk. This is why many clinicians interpret galectin-3 beside creatinine and eGFR rather than reading it alone.
Inflammation can also complicate interpretation. Galectin-3 is involved in immune signaling, so a value may be higher during inflammatory illness. If someone has fever, infection, recent surgery, uncontrolled autoimmune disease, or another active inflammatory condition, the timing of the test matters. In that setting, a repeat test after recovery may be more informative.
Age is another factor. Older adults are more likely to have higher galectin-3 levels because they are more likely to have kidney disease, vascular disease, cardiac remodeling, and chronic inflammatory burden. This does not mean an older person should ignore a high result. It means the result should be interpreted with age-appropriate context.
Galectin-3 is also not specific enough to diagnose fibrosis in one organ. A high value cannot prove cardiac fibrosis, liver fibrosis, or lung fibrosis by itself. Imaging, organ-specific blood tests, clinical history, and sometimes specialist evaluation are needed to locate the problem.
How Doctors Interpret Galectin-3 With Other Tests
Doctors rarely make decisions from galectin-3 alone. They compare it with symptoms, physical findings, imaging, medication history, kidney function, and other biomarkers. This combined approach reduces the risk of overreacting to a single abnormal number.
| Marker | Main signal | Where it helps most |
|---|---|---|
| Galectin-3 | Inflammation, fibrosis, remodeling risk | Long-term risk assessment in heart failure |
| BNP or NT-proBNP | Heart stretch, pressure, fluid overload | Diagnosing and monitoring heart failure |
| Troponin | Heart muscle injury | Heart attack evaluation and myocardial injury |
| Creatinine and eGFR | Kidney filtration | Checking whether kidney disease affects symptoms and biomarker levels |
| hs-CRP | General inflammation | Cardiovascular inflammatory risk and systemic inflammation context |
Symptoms remain central. Shortness of breath, fatigue, ankle swelling, rapid weight gain, trouble lying flat, waking up breathless, and reduced exercise tolerance all make a high galectin-3 result more concerning. Without symptoms or other abnormal findings, a mild elevation may call for follow-up rather than urgent action.
The echocardiogram is also important. It can show whether the heart’s ejection fraction is reduced, whether the heart muscle is thickened, whether the left atrium is enlarged, whether valves are leaking or narrowed, and whether diastolic dysfunction is present. Galectin-3 can support concern about remodeling, but imaging shows structure and function.
BNP or NT-proBNP can help determine whether current symptoms are likely related to heart failure. If natriuretic peptides are high and galectin-3 is also high, doctors may see both pressure-related stress and fibrosis-related risk. If BNP or NT-proBNP is low, active heart failure becomes less likely, though not impossible in every situation.
Kidney tests help prevent misinterpretation. A kidney function blood test panel can show whether reduced filtration, electrolyte problems, or fluid balance issues are contributing to the clinical picture.
Inflammatory markers may help when infection, autoimmune disease, or vascular inflammation is part of the question. A marker such as hs-CRP does not explain galectin-3 by itself, but it can show whether a broader inflammatory pattern is present.
Trend can matter more than a single result. A galectin-3 value that stays high or rises over repeated tests may carry more concern than one isolated result. However, serial testing should only be done when it will guide care. Repeating markers without a plan can create anxiety without improving decisions.
Preparation, Timing, and Test Limitations
The galectin-3 blood test is a standard venous blood draw. Fasting is usually not required for galectin-3 itself. If the test is ordered with cholesterol, glucose, or other fasting labs, the instructions may be based on those other tests. Follow the lab or clinician’s directions for the full order.
Most people do not need to stop medications before the test. Do not stop heart failure medicines, blood pressure medicines, diuretics, diabetes medicines, or blood thinners unless the prescribing clinician tells you to. Medication changes before testing can be risky and may make results harder to interpret.
Results may come back in a few days, depending on whether the sample is processed locally or sent to a reference laboratory. Galectin-3 is not usually used as a rapid emergency-room decision test in the way troponin or BNP may be used.
The main limitations are specificity and actionability. Specificity means how well a test points to one particular disease. Galectin-3 is not highly specific because several organs and conditions can raise it. Actionability means whether a result clearly tells the clinician what to do next. Galectin-3 may refine risk, but it does not automatically point to one medication, procedure, or diagnosis.
Important limitations include:
- It does not diagnose heart failure by itself.
- It does not rule out heart failure when normal.
- It does not diagnose a heart attack.
- It does not locate fibrosis in the heart, liver, lungs, or kidneys.
- It can be affected by kidney function.
- It may rise with non-cardiac inflammation or fibrosis.
- Different assays may produce different reference intervals.
- It is more useful for risk assessment than for day-to-day symptom decisions.
Insurance coverage and availability vary. Some clinics use galectin-3 regularly in advanced biomarker panels, while others rarely order it. The test has not replaced BNP, NT-proBNP, troponin, echocardiography, or guideline-based heart failure evaluation.
What to Do After a Galectin-3 Result
A galectin-3 result is most useful when it leads to a clear next step. The next step depends on the number, symptoms, medical history, and other test results.
If galectin-3 is high and you already have heart failure, ask how the result changes your risk category. It may support closer follow-up, a medication review, attention to fluid status, better blood pressure control, or evaluation for causes of worsening symptoms. In chronic heart failure, the result may also encourage more careful tracking of weight, swelling, blood pressure, kidney function, and exercise tolerance.
If galectin-3 is high but you do not have a heart failure diagnosis, the next step is usually not to assume heart failure. A clinician may review symptoms, repeat the test, check BNP or NT-proBNP, order an echocardiogram, assess kidney function, and look for inflammatory or fibrotic conditions. The result may be a reason to investigate, not a diagnosis.
If galectin-3 is normal but symptoms are present, do not dismiss the symptoms. Heart failure, valve disease, coronary artery disease, lung disease, anemia, thyroid disease, kidney disease, and deconditioning can all cause overlapping symptoms. A normal galectin-3 value does not replace a proper evaluation.
Seek urgent medical care if you have chest pressure, severe shortness of breath, fainting, confusion, blue lips, coughing pink frothy sputum, new one-sided weakness, oxygen levels that are low, or sudden rapid swelling with trouble breathing. These situations need immediate assessment and should not wait for a biomarker result.
For non-urgent follow-up, useful questions include:
- What reference range did this lab use?
- Is my result high enough to change my risk category?
- How do my BNP or NT-proBNP results compare?
- Are my creatinine and eGFR affecting the result?
- Does my echocardiogram show stiffness, enlargement, valve disease, or reduced pumping function?
- Should the test be repeated, and if so, when?
- What treatment or monitoring decision depends on this result?
Lifestyle and medical treatment should focus on the conditions driving risk. For many people, that means controlling blood pressure, managing diabetes, treating sleep apnea, reducing excess sodium when advised, taking heart failure medicines as prescribed, staying physically active within safe limits, and keeping follow-up appointments. Galectin-3 may describe risk, but risk improves through diagnosis-specific care.
References
- Serum Galectin-3 and Risk Stratification in Chronic Heart Failure: A Systematic Review of Mortality Outcomes 2025 (Systematic Review)
- Galectin-3 levels and long-term all-cause mortality and hospitalization in heart failure patients: a meta-analysis 2024 (Systematic Review)
- Galectin-3 is Associated with Heart Failure Incidence: A Meta-Analysis 2023 (Meta-Analysis)
- The Role of Galectin-3 in Heart Failure-The Diagnostic, Prognostic and Therapeutic Potential-Where Do We Stand? 2023 (Review)
- Clinical Implications of Plasma Galectin-3 in Heart Failure With Preserved Ejection Fraction: A Meta-Analysis 2022 (Meta-Analysis)
- 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines 2022 (Guideline)
Disclaimer
Galectin-3 results should be interpreted by a qualified clinician who can review symptoms, medical history, kidney function, imaging, and other cardiac biomarkers. A high result does not diagnose heart failure or a heart attack by itself. Seek urgent medical care for chest pain, severe shortness of breath, fainting, confusion, or sudden worsening swelling.
